Valuation: HLS Therapeutics Inc.

Market Cap 82.64M 73.43M 68.53M 62.47M 118M 7.94B 119M 829M 321M 4.06B 310M 304M 13.03B P/E 2026 *
-13.1x
P/E 2027 * -38.8x
Enterprise Value 82.64M 73.43M 68.53M 62.47M 118M 7.94B 119M 829M 321M 4.06B 310M 304M 13.03B EV / Sales 2026 *
1.42x
EV / Sales 2027 * 1.27x
Free-Float
99.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week-3.73%
Current month-7.86%
1 month+7.20%
3 months-8.94%
6 months-12.05%
Current year-19.71%
1 week 3.75
Extreme 3.75
4.2
1 month 3.6
Extreme 3.6
4.2
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.72
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 2023-04-30
Director of Finance/CFO 61 2024-01-25
Chief Tech/Sci/R&D Officer 61 2014-05-31
Director TitleAgeSince
Director/Board Member 58 2018-03-11
Chairman 48 2023-06-21
Director/Board Member 65 2020-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Buy

Compliance Officer

2,000 0.0064%
9/1/26 Buy

Chief Financial Officer

2,000 0.0064%
8/28/26 TaxCompany -2,000 0.0064% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%-3.73%-29.89%-23.52% 82.64M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.26%-3.43%+21.47%+49.09% 369.73B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.95%

Financials

2026 *2027 *
Net sales 58.34M 51.83M 48.38M 44.09M 83.16M 5.61B 83.94M 585M 227M 2.87B 219M 214M 9.2B 65.06M 57.8M 53.95M 49.17M 92.74M 6.25B 93.61M 653M 253M 3.2B 244M 239M 10.26B
Net income -5.47M -4.86M -4.54M -4.13M -7.8M -526M -7.87M -54.89M -21.27M -269M -20.54M -20.09M -863M -2.16M -1.92M -1.79M -1.64M -3.09M -208M -3.11M -21.72M -8.42M -106M -8.13M -7.95M -341M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
26-10-02 $3.870 -0.51% 51,573
26-10-01 $3.890 -7.38% 388,910
26-09-30 $4.200 +5.26% 104,828
26-09-29 $3.990 -0.25% 19,136
26-09-28 $4.000 -0.50% 28,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.715USD
Average target price
5.270USD
Spread / Average Target
+94.13%

Quarterly revenue - Rate of surprise